Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib.

Authors :: Lucà MG
Nani R
Schranz M
De Giorgio M
Iegri C
Agazzi R
Sala F
Virotta G
Sarti D
Conte G
Pinelli D
Nicora C
Colledan M
Sironi S
Fagiuoli S
Source :: Future oncology (London, England) [Future Oncol] 2018 Apr; Vol. 14 (8), pp. 727-735. Date of Electronic Publication: 2018 Mar 26.
Publication Year :: 2018
Abstract: Aim: The aim was to evaluate cost-effectiveness of yttrium-90 transarterial radioembolization (TARE) in comparison to sorafenib treatment.<br />Patients & Methods: A single-center, retrospective, observational study was performed, 166 patients with intermediate-/advanced-stage hepatocellular carcinoma were treated with sorafenib and 19 with TARE. The patients out of the sorafenib group matching the inclusion criteria for TARE, were reassigned to a subgroup SOR3.<br />Results: Mean costs for SOR3 patients amounted to €27,992 per patient, instead for TARE treatment, mean expense per patient was €17,761 (p = 0.028). Overall survival was similar between the two groups, while midterm survival rates (p = 0.012) were significantly higher with TARE treatment.<br />Conclusion: TARE causes significantly lower treatment costs than sorafenib with better outcome in midterm survival.

Full Text Access

Tools